Samsung's biologics plant in South Korea receives Form 483 over data integrity, other observations
FDA inspectors uncovered data integrity concerns with Samsung’s biologics plant, according to a Form 483 released this week following a 10-day agency inspection of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.